Survival in Sickle Cell Disease: Data from a Well-Resourced, National Health System Setting
Authors: Gardner Kate , Douiri Abdel , Allman Marlene , Drasar Emma , Awogbade Moji , Thein Swee Lay 
Published: October 2019

Background: In well-resourced countries, early mortality in sickle cell disease (SCD) is no longer a major feature, thus the burden of SCD mortality has shifted to adults. Recent data on patients with SCD in USA confirmed continuing improvement in adult survival, attributed to better preventative care. Health economics may play a key role in clinical outcome in SCD; we hypothesise that survival would be longer in a system which is not insurance based. King's College Hospital, London, UK has a large SCD cohort in a well-resourced setting within a national health service framework.

Methods: 712 adult (≥18 years) SCD patients were observed over 10 years (2004-13 inclusive) to identify mortality outcome (total 5268 patient-years of observation with median 8 years of observation per patient, over median 9 total hospital visits). Demographic data, sickle and alpha genotype were documented. Laboratory data were also collected (list in table): outpatient laboratory values were averaged over the 10 year period to create a "steady state" value for each patient. Mean number of hospital admissions with a sickle pain crisis was calculated (total admissions/number of observed years per patient).

IBM SPSS Statistics 22 was used for Kaplan Meier survival analysis and then regression analysis was undertaken, based on the Cox proportional hazards model, to identify variables which were associated with mortality, and produce hazard ratios for putative predictors (demographic, laboratory and admission data).

Results: 43 patients (6.0%) died during the study at a median age of 42 years (IQR: 31-48). Kaplan Meier analysis showed an estimated median survival of 77 years (95% CI: 68-85) for all sickle genotypes. Sub-analysis by sickle genotype showed: HbSS/HbSβ0 thalassaemia together (33 deaths in 450 patients) with estimated median survival 67 years; and HbSC (8 deaths in 229 patients) with significantly higher estimated median survival 82 years (p<0.001), see figure 1. For both genotypes, there was no gender difference on sub-analysis. For HbSS/HbSβ0, there was a significant difference by hospitalisation rate with survival: median survival in those with ≤0.5 admissions/year was 67 years, significantly higher than 60 years (CI: 43-77) for high admission rates (p=0.001), see figure 2.

Cox regression analysis was conducted for HbSS/HbSβ0 patients (demographic, laboratory and admission data), see table. Risk of death is increased: 2.5-fold if ferritin is high (>1000ug/L), 6% for every extra 10umol/L total bilirubin, 20% for every extra 100 IU/L LDH, 18% for every extra 1 x109/L WBC (all steady state values). Hospitalisation rates were analysed two ways: using the continuous variable, risk of death is increased by 37% for every admission accrued in an individual's mean admission/year statistic; and using a dichotomous variable (high versus low admissions), those with high admission rates have a hazard ratio over 3-fold that of those with low admission rates.

Conclusions: These data indicate that adult survival in SCD in our institution is high; estimated median survival of 67 years for HbSS/Sβ0 and 82 years for HbSC. This is markedly longer than those recently quoted from the USA, which may be due to disparities in health economics. Cox regression sub-analysis for the HbSS/Sβ0 group reveals multiple "predictors" of increased mortality risk including classical laboratory markers of SCD severity - iron loading (likely correlated with disease severity via transfusion rate), inflammatory and haemolytic parameters - as well as confirming hospitalisation rate as a simple but strong predictor of survival in SCD.

Table. Cox regression analysis for HbSS/HbSβ0 thalassaemia HbSS/HbSβ0 thalassaemia (n=450, 33 deaths) Hazard ratio (CI) p value Demographics Alpha Thalassaemia* 1.342 (0.666-2.706) 0.411 Sex* (M=default) 0.674 (0.339-1.340) 0.261 Laboratory Total bilirubin umol/L 1.006 (1.004-1.008) <0.000001 C-reactive protein (CRP) mg/L 1.019 (0.998-1.042) 0.079 High Ferritin >1000ug/L* 2.518 (1.212-5.232) 0.013 Lactate dehydrogenase (LDH) IU/L 1.002 (1.000-1.004) 0.038 WBC x109/L 1.181 (1.037-1.345) 0.012 Hb g/L 0.979 (0.956-1.002) 0.073 Reticulocytes x109/L 1.002 (0.999-1.005) 0.285 Admissions Mean number admissions / year 1.374 (1.159-1.630) <0.001 High admission rate (>0.5/year) 3.131 (1.567-6.259) 0.001 *Dichotomous variables

Disclosures

No relevant conflicts of interest to declare.